365 related articles for article (PubMed ID: 34342738)
1. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
[TBL] [Abstract][Full Text] [Related]
3. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
Xiang S; Shen R; Xiang J; Zhu N; Gu J; Shen J; Zhang Y; Ge H
Expert Opin Drug Saf; 2024 May; 23(5):627-636. PubMed ID: 38456691
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
5. Managing toxicities of Bruton tyrosine kinase inhibitors.
Lipsky A; Lamanna N
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698
[TBL] [Abstract][Full Text] [Related]
6. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
Awan FT; Addison D; Alfraih F; Baratta SJ; Campos RN; Cugliari MS; Goh YT; Ionin VA; Mundnich S; Sverdlov AL; Tam C; Ysebaert L
Blood Adv; 2022 Sep; 6(18):5516-5525. PubMed ID: 35790105
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Dong R; Yan Y; Zeng X; Lin N; Tan B
Drug Des Devel Ther; 2022; 16():3225-3239. PubMed ID: 36164415
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG
Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38831641
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.
Patel JN; Singh J; Ghosh N
Oncotarget; 2024 Jun; 15():355-359. PubMed ID: 38829647
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Wolska-Washer A; Robak P; Witkowska M; Robak T
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
[TBL] [Abstract][Full Text] [Related]
13. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Xiao L; Salem JE; Clauss S; Hanley A; Bapat A; Hulsmans M; Iwamoto Y; Wojtkiewicz G; Cetinbas M; Schloss MJ; Tedeschi J; Lebrun-Vignes B; Lundby A; Sadreyev RI; Moslehi J; Nahrendorf M; Ellinor PT; Milan DJ
Circulation; 2020 Dec; 142(25):2443-2455. PubMed ID: 33092403
[TBL] [Abstract][Full Text] [Related]
15. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
16. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
17. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors.
Zhai Y; Hu F; Shi W; Ye X; Xu J; Guo X; Cao Y; He J; Xu F
Expert Opin Drug Saf; 2023; 22(9):857-869. PubMed ID: 37070462
[TBL] [Abstract][Full Text] [Related]
19. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
Fleming MR; Xiao L; Jackson KD; Beckman JA; Barac A; Moslehi JJ
Circ Res; 2021 Jun; 128(12):1973-1987. PubMed ID: 34110908
[TBL] [Abstract][Full Text] [Related]
20. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
